Search

Your search keyword '"Aston, Roger"' showing total 17 results
Start Over Author "Aston, Roger"
17 results on '"Aston, Roger"'

3. Nanotechnology applications for drug delivery: nanotechnology is believed to hold enormous promise for the future of medicine and healthcare. This review provides an update of how the convergence of biology, chemistry, physical sciences and molecular engineering that defines nanotechnology is being applied to the development of novel systems for the delivery of a wide range of therapeutic entities

Author

Aston, Roger, Saffie-Siebert, Roghieh, Canham, Leigh, and Ogden, Jill

Subjects
Pharmaceutical industry -- Product development, Drug delivery systems -- Product development, Nanotechnology -- Research, Nanotechnology -- Usage, Drugs -- Vehicles, Drugs -- Product development, Business, Pharmaceuticals and cosmetics industries
Abstract

Nanotechnology is somewhat of a 'catch-all' term used to describe a wide range of enabling technologies focussed at the level of atoms and molecules, and is applicable to many different [...]

Published
2005

12. Monoclonal antibodies to bovine growth hormone potentiate effects of the hormone on somatomedin C levels and growth of hypophysectomized rats

Author

Wallis, Michael, Daniels, Margaret, Ray, Keith P., Cottingham, Janet D., and Aston, Roger

Abstract

Bovine growth hormone (50 μg/day) elevated somatomedin C levels in plasma of hypophysectomized rats: the effect was seen 12 h after the first injection and was sustained throughout a 7-day treatment period. When monoclonal antibodies to bovine growth hormone were administered with the hormone the stimulation of somatomedin C levels was markedly enhanced, as were effects on body weight. Each one of a panel of 7 monoclonal antibodies potentiated the actions of the hormone on growth and somatomedin C levels, though the extent and pattern of potentiation varied considerably from one antibody to another. Effects on growth and somatomedin C levels correlated fairly well, though there were some discrepancies.

Published
1987
Full Text
View/download PDF

17. A preliminary assessment of oral monepantel's tolerability and pharmacokinetics in individuals with treatment-refractory solid tumors

Author

Erinna F. Lee, W. Douglas Fairlie, Gonzalo Tapia Rico, Roger Aston, Tiffany J Harris, Richard Anthony Mollard, Michael P. Brown, Anna Rachelle Mislang, Mislang, Anna, Mollard, Richard, Tapia Rico, Gonzalo, Fairlie, W Douglas, Lee, Erinna F, Harris, Tiffany J, Aston, Roger, and Brown, MP

Subjects
0301 basic medicine, Cancer Research, anthilmintric, Pharmacology, Toxicology, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, medicine, Pharmacology (medical), Anthelmintic, Tumor marker, Treatment refractory, business.industry, monepantel, phase I study, Safety profile, 030104 developmental biology, Oncology, Tolerability, 030220 oncology & carcinogenesis, Pharmacodynamics, Cohort, business, medicine.drug
Abstract

Purpose: Monepantel is an approved veterinary anthelmintic with a strong safety profile. Preclinical evidence suggests novel mTOR pathway-associated anticancer activity. An open-label Phase I trial assessed tolerability, pharmacokinetics, pharmacodynamics and PET-CT imaging following oral Zolvix® monepantel administration to adults with treatment refractory, progressing and unresectable solid tumors. Methods: Subjects were scheduled to daily home-based monepantel administration for 28 days in a 3 + 3 dose escalation study (5.0, 25.0 and 62.5 mg/kg bw). Results: Of 41 reported drug-related AEs, 68% were Grade 1 and 24% were Grade 2; 35 AEs related to gastrointestinal effects including very poor palatability. DLT and MTD could not be determined due to early termination. Myelosuppression was not observed at the lowest level tested. Three of four Cohort 1 subjects had reduced mTOR pathway marker p-RPS6KB1 levels in PBMCs and achieved RECISTv1.1 SD by CT; one had progressive bony metastases by FDG-PET. One subject recorded PD on day 28, correlating with no detectable plasma monepantel from day 7. Monepantel sulfone dominated monepantel in pharmacokinetics. Both Cohort 2 subjects withdrew early due to AEs and the trial was terminated. Conclusions: Short-term 5 mg/kg bw monepantel administration provides a combined steady-state trough plasma monepantel and monepantel sulfone concentration of 0.5 μM. Gastrointestinal AEs including very poor palatability are concerning and suggested to be resolved by future drug product reformulation. RECISTv1.1, p-RPS6KB1 and plasma tumor marker outcomes provide preliminary evidence of anticancer activity. Refereed/Peer-reviewed

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results